Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00252200 · ClinicalTrials.gov registry record · Phase 1
BNP (Nesiritide) vs. Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery.
A Phase 1 study of Acute Kidney Failure, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00252200: Completed Phase 1 study of Acute Kidney Failure, sponsored by Mayo Clinic.
NCT00252200 is a Phase 1 study of Acute Kidney Failure that has completed, run by Mayo Clinic. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00252200, a Phase 1 study of Acute Kidney Failure, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Use of BNP (nesiritide) vs placebo to help protect kidney function in patients undergoing heart bypass surgery.
Conditions Studied
Interventions
- DRUG Neseritide
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2003-03 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00252200
The ClinicalTrials.gov registry entry for NCT00252200 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Kidney Failure appearing as the primary indexed condition, and to 1 intervention - of which Neseritide is the first listed.
NCT00252200 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00252200 about?
NCT00252200 is a clinical study titled "BNP (Nesiritide) vs. Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery.". Use of BNP (nesiritide) vs placebo to help protect kidney function in patients undergoing heart bypass surgery.
What is the current status of trial NCT00252200?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2003-03. Estimated completion is 2007-10.
What conditions does trial NCT00252200 study?
This clinical trial studies the following conditions: Acute Kidney Failure.
What interventions are being tested in trial NCT00252200?
The interventions under investigation include: Neseritide (DRUG).
Who is sponsoring clinical trial NCT00252200?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00252200 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Kidney Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.